Mural Oncology plc (MURA)

Market Cap	62.61M
Revenue (ttm)	n/a
Net Income (ttm)	-207.45M
Shares Out	16.92M
EPS (ttm)	-12.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,609
Open	3.710
Previous Close	3.700
Day's Range	3.670 - 3.805
52-Week Range	3.230 - 6.250
Beta	n/a
Analysts	Buy
Price Target	13.00 (+250.4%)
Earnings Date	May 15, 2024

About MURA

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: MURA

Analyst Forecast

According to one analyst, the rating for MURA stock is "Buy" and the 12-month stock price forecast is $13.0.

Price Target

$13.0

(250.40% upside)

Analyst Consensus: Buy